Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.

Marzia Occhino, Lizzia Raffaghello, Oscar Burrone, Claudio Gambini, Vito Pistoia, Maria Valeria Corrias, Marco Bestagno

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

GD2 is a disialoganglioside expressed at high density on the surface of malignant cells of neuroectodermal origin, especially in neuroblastoma (NB) and melanoma. Since its expression in normal tissues is very restricted, GD2 represents an excellent target for neuroectodermal tumor targeting. Mini-antibody technology allows the production of dimeric single-chain antibodies, also called small immunoproteins (SIPs), which are composed of a scFv fused to a dimerizing domain of immunoglobulin heavy chains. Dimerization results in an increase of the total apparent affinity and a slower clearance in vivo than scFvs. These properties make SIPs very attractive molecules for tumor targeting. We isolated the variable regions from an anti-GD2 monoclonal antibody and exploited the SIP technology to generate two novel anti-GD2 SIPs. The first anti-GD2 SIP is a fully murine molecule containing the CH3 domain of mouse IgG1, whereas the second construct is a hybrid mouse-human molecule containing the CH4 domain of human IgE. Both mini-antibodies were successfully produced and shown to retain binding specificity as well as an affinity similar to that of the original antibody.

Original languageEnglish
Pages (from-to)383-388
Number of pages6
JournalInternational Journal of Molecular Medicine
Volume14
Issue number3
Publication statusPublished - Sep 2004

Fingerprint

Immunoproteins
Neuroblastoma
Antigens
Antibodies
Neuroectodermal Tumors
Technology
Single-Chain Antibodies
Immunoglobulin Heavy Chains
Dimerization
Immunoglobulin E
Melanoma
Immunoglobulin G
Monoclonal Antibodies

ASJC Scopus subject areas

  • Genetics

Cite this

Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2. / Occhino, Marzia; Raffaghello, Lizzia; Burrone, Oscar; Gambini, Claudio; Pistoia, Vito; Corrias, Maria Valeria; Bestagno, Marco.

In: International Journal of Molecular Medicine, Vol. 14, No. 3, 09.2004, p. 383-388.

Research output: Contribution to journalArticle

@article{875e7d11db8b4c0db984bb2d5bd60e77,
title = "Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.",
abstract = "GD2 is a disialoganglioside expressed at high density on the surface of malignant cells of neuroectodermal origin, especially in neuroblastoma (NB) and melanoma. Since its expression in normal tissues is very restricted, GD2 represents an excellent target for neuroectodermal tumor targeting. Mini-antibody technology allows the production of dimeric single-chain antibodies, also called small immunoproteins (SIPs), which are composed of a scFv fused to a dimerizing domain of immunoglobulin heavy chains. Dimerization results in an increase of the total apparent affinity and a slower clearance in vivo than scFvs. These properties make SIPs very attractive molecules for tumor targeting. We isolated the variable regions from an anti-GD2 monoclonal antibody and exploited the SIP technology to generate two novel anti-GD2 SIPs. The first anti-GD2 SIP is a fully murine molecule containing the CH3 domain of mouse IgG1, whereas the second construct is a hybrid mouse-human molecule containing the CH4 domain of human IgE. Both mini-antibodies were successfully produced and shown to retain binding specificity as well as an affinity similar to that of the original antibody.",
author = "Marzia Occhino and Lizzia Raffaghello and Oscar Burrone and Claudio Gambini and Vito Pistoia and Corrias, {Maria Valeria} and Marco Bestagno",
year = "2004",
month = "9",
language = "English",
volume = "14",
pages = "383--388",
journal = "International Journal of Molecular Medicine",
issn = "1107-3756",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.

AU - Occhino, Marzia

AU - Raffaghello, Lizzia

AU - Burrone, Oscar

AU - Gambini, Claudio

AU - Pistoia, Vito

AU - Corrias, Maria Valeria

AU - Bestagno, Marco

PY - 2004/9

Y1 - 2004/9

N2 - GD2 is a disialoganglioside expressed at high density on the surface of malignant cells of neuroectodermal origin, especially in neuroblastoma (NB) and melanoma. Since its expression in normal tissues is very restricted, GD2 represents an excellent target for neuroectodermal tumor targeting. Mini-antibody technology allows the production of dimeric single-chain antibodies, also called small immunoproteins (SIPs), which are composed of a scFv fused to a dimerizing domain of immunoglobulin heavy chains. Dimerization results in an increase of the total apparent affinity and a slower clearance in vivo than scFvs. These properties make SIPs very attractive molecules for tumor targeting. We isolated the variable regions from an anti-GD2 monoclonal antibody and exploited the SIP technology to generate two novel anti-GD2 SIPs. The first anti-GD2 SIP is a fully murine molecule containing the CH3 domain of mouse IgG1, whereas the second construct is a hybrid mouse-human molecule containing the CH4 domain of human IgE. Both mini-antibodies were successfully produced and shown to retain binding specificity as well as an affinity similar to that of the original antibody.

AB - GD2 is a disialoganglioside expressed at high density on the surface of malignant cells of neuroectodermal origin, especially in neuroblastoma (NB) and melanoma. Since its expression in normal tissues is very restricted, GD2 represents an excellent target for neuroectodermal tumor targeting. Mini-antibody technology allows the production of dimeric single-chain antibodies, also called small immunoproteins (SIPs), which are composed of a scFv fused to a dimerizing domain of immunoglobulin heavy chains. Dimerization results in an increase of the total apparent affinity and a slower clearance in vivo than scFvs. These properties make SIPs very attractive molecules for tumor targeting. We isolated the variable regions from an anti-GD2 monoclonal antibody and exploited the SIP technology to generate two novel anti-GD2 SIPs. The first anti-GD2 SIP is a fully murine molecule containing the CH3 domain of mouse IgG1, whereas the second construct is a hybrid mouse-human molecule containing the CH4 domain of human IgE. Both mini-antibodies were successfully produced and shown to retain binding specificity as well as an affinity similar to that of the original antibody.

UR - http://www.scopus.com/inward/record.url?scp=16644372414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644372414&partnerID=8YFLogxK

M3 - Article

C2 - 15289889

AN - SCOPUS:16644372414

VL - 14

SP - 383

EP - 388

JO - International Journal of Molecular Medicine

JF - International Journal of Molecular Medicine

SN - 1107-3756

IS - 3

ER -